Changes in the Use of Opioids, Antidepressants, and Benzodiazepines in Rheumatoid Arthritis Patients Treated With Biologic Agents
NCT ID: NCT01137838
Last Updated: 2011-05-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1810 participants
OBSERVATIONAL
2009-10-31
2010-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Depression and Anxiety in Rheumatoid Arthritis
NCT02122406
Probing the Rheumatoid Arthritis Brain to Elucidate Central Pain Pathways
NCT05693532
Anxiety Depression and Rheumatoid Arthritis
NCT03061877
Chronic Pain in Rheumatoid Arthritis
NCT05038553
Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease
NCT04817072
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with RA and new to abatacept
No interventions assigned to this group
Patients with RA and new to infliximab
No interventions assigned to this group
Patients with RA and new to etanercept
No interventions assigned to this group
Patients with RA and new to adalimumab
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented first biologic prescription ("index" prescription) for abatacept, infliximab, etanercept, or adalimumab
* Continuous therapy (gap between scripts no greater than 150% days supply) for minimum 6 months from index
* Prescription claims data available for 6 months before and 12 months after index biologic prescription
* Continuous eligibility for 6 months before and 12 months after index biologic prescription
Exclusion Criteria
* Prescriptions not continuous for at least 6 months
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bristol-Myers Squibb
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trials Disclosure
Investigator Inquiry form
For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-238
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.